HEALTH

Johnson & Johnson to Divest Cordis Unit: The New Brunswick, N.J., drug and health-care products company has agreed to divest Cordis Corp.’s neurological products business to settle antitrust charges over its planned $1.8-billion acquisition of the medical device maker. A Federal Trade Commission complaint had said that the Johnson & Johnson-Cordis merger would have given the two companies control of 85% of the neurological shunt market, according to Federal Filings Business News. Johnson & Johnson spokesman Robert Kniffin said he believes the agreement with the FTC was the final regulatory hurdle the two companies had to clear before consummating their union.